Skip to main content
Premium Trial:

Request an Annual Quote

Early Trial Responses

A small trial suggests that combining an immunotherapy and an AKT inhibitor may be a viable treatment for some people with brain cancer, the Guardian reports.

As part of the Phase 1 Ice-CAP trial, 10 people with advanced glioblastoma, seven of whom had PTEN mutations and three of whom had complete loss of PTEN expression in their tumors, were treated with a combination of atezolizumab and ipatasertib, according to the UK's Institute of Cancer Research. It adds that atezolizumab is an immunotherapy, while ipatasertib is a precision drug that blocks AKT. As the ICR-led researchers reported at the American Association for Cancer Research annual meeting, two patients in the small, early-stage trial responded well to the treatment.

According to the Guardian, one patient, Hamish Mykura, who was diagnosed with glioblastoma in 2018, says there are no signs of his tumor on scans.

"Patients with glioblastoma have very poor survival rates, and even fewer new treatment options coming through, so any advance in outcomes would be extremely welcome," study leader Junita Lopez from ICR says in a statement.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more